Investor Presentation Q1 2023

67 Investor presentation First three months of 2023 The SELECT cardiovascular outcomes trial expected to complete in the middle of 2023 Novo NordiskⓇ SELECT trial with 17,500 people with obesity and established CVD Semaglutide 2.4 mg R 1:1 Placebo Objective Demonstrate that semaglutide s.c. 2.4 mg OW lowers the incidence MACE vs. placebo when both added to standard of care in subjects with established CV disease and overweight or obesity. Primary endpoint Time from randomisation to first occurrence of 3-point MACE¹ Secondary confirmatory endpoints Time from randomisation to first occurrence of CV death • HF composite endpoint • All-cause death Selected Secondary Supportive endpoints Event driven 5 weeks · 5-point MACE composite follow-up • 5-component composite nephropathy endpoint • Glucose metabolism endpoints and other metabolic parameters Estimated completion The trial is expected to complete in the middle of 2023 1MACE includes non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death. MACE: Major adverse cardiovascular events; HF: Heart failure; CV: Cardiovascular; CVD: Cardiovascular Disease

View entire presentation